Article
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.
Clinics (Sao Paulo, Brazil) - 1 Jun 2017
Callefi Luciana Azevedo, Villela-Nogueira Cristiane Alves, de Barros Tenore Simone, Carnaúba-Júnior Dimas, Coelho Henrique Sérgio Moraes, Pinto Paulo de Tarso A, Nabuco Letícia Cancella, Pessoa Mário Guimarães, Ferraz Maria Lucia Cardoso Gomes, Ferreira Paulo Roberto Abrão, de Lourdes Candolo Martinelli Ana, Chachá Silvana Gama Florencio, de Souza Paiva Ferreira Adalgisa, de Macedo Bisio Alessandra Porto, Brandão-Mello Carlos Eduardo, Álvares-Da-Silva Mário Reis, Reuter Tânia, Ivantes Claudia Alexandra Pontes, de Mello Perez Renata, Mendes-Correa Maria Cássia Jacintho
Abstract excerpt
OBJECTIVE:: To evaluate the effectiveness and safety of first-generation protease inhibitors for the treatment of genotype 1 hepatitis C virus-infected patients at Brazilian reference centers. METHODS:: This multicenter cross-sectional study included hepatitis C virus genotype 1 monoinfected patients treated with Peg-interferon, ribavirin, and either boceprevir (n=158) or telaprevir (n=557) between July 2013 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.